Ciraparantag
Ciraparantag (aripazine) is a drug under investigation as an antidote for a number of anticoagulant (anti-blood clotting) drugs, including factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), dabigatran, and heparins (including fondaparinux, low molecular weight heparins (LMWH), and unfractionated heparin).[1][2]
Clinical data | |
---|---|
Other names | PER977; N1,N1′-[Piperazine-1,4-diylbis(propane-1,3-diyl)]bis-L-argininamide |
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Onset of action | 10 min |
Duration of action | 24 hours |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C22H48N12O2 |
Molar mass | 512.708 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Medical uses
Ciraparantag significantly reverses anticoagulation induced by a therapeutic dose of edoxaban within 10 minutes following injection.[3] This return to normal haemostasis persists over 24 hours following a single intravenous dose of the drug.[4] In addition to edoxaban, it also reverses the actions of LMWH and dabigatran.[5]
Pharmacology
Mechanism of action
According to in vitro studies, the substance binds directly to anticoagulants via hydrogen bonds and charge-charge interactions [3] from or to various parts of the molecule:[1]
Hydrogen bonds | Rivaroxaban | Apixaban | Edoxaban | Dabigatran | Heparins |
---|---|---|---|---|---|
Guanidine part | |||||
α-Amino group | |||||
Amide nitrogen | |||||
Amide oxygen |
Chemistry
Ciraparantag consists of two L-arginine units connected with a piperazine containing linker chain.[1]
References
- Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel Herbst 2015 (in German)
- Ansell, J. E. (2015). "Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants". Journal of Thrombosis and Thrombolysis. 41 (2): 248–52. doi:10.1007/s11239-015-1288-1. PMID 26449414.
- Ansell, Jack E.; Bakhru, Sasha H.; Laulicht, Bryan E.; Steiner, Solomon S.; Grosso, Michael A.; Brown, Karen; Dishy, Victor; Lanz, Hans J.; Mercuri, Michele F.; Noveck, Robert J.; Costin, James C. (February 2017). "Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban". Thrombosis and Haemostasis. 117 (2): 238–245. doi:10.1160/TH16-03-0224. ISSN 0340-6245. PMC 6260118. PMID 27853809.
- Laulicht B, Bakhru S, Jiang X et al.Antidote for new oral anticoagulants: Mechanism of action and binding specificity of PER977Internat’l Soc Thromb & Haemost2013. Abstracthttp://www.eventure-online.com/eventure/publicAbstractView.do?id=226718&congressId=6839andhttp://www.perosphere.com/content/presentations/documents/Perosphere_ISTH_Talk
- Costin, James C.; Laulicht, Bryan; Bakhru, Sasha; Steiner, Solomon (March 2015). "PER977 reverses low molecular weight heparin in addition to IIa and Xa new oral anticoagulants". Journal of the American College of Cardiology. 65 (10): A2056. doi:10.1016/S0735-1097(15)62056-3.